Nature Communications (Apr 2022)
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
- Tianyu Cai,
- Agnès Gouble,
- Kathryn L. Black,
- Anna Skwarska,
- Ammar S. Naqvi,
- Deanne Taylor,
- Ming Zhao,
- Qi Yuan,
- Mayumi Sugita,
- Qi Zhang,
- Roman Galetto,
- Stéphanie Filipe,
- Antonio Cavazos,
- Lina Han,
- Vinitha Kuruvilla,
- Helen Ma,
- Connie Weng,
- Chang-Gong Liu,
- Xiuping Liu,
- Sergej Konoplev,
- Jun Gu,
- Guilin Tang,
- Xiaoping Su,
- Gheath Al-Atrash,
- Stefan Ciurea,
- Sattva S. Neelapu,
- Andrew A. Lane,
- Hagop Kantarjian,
- Monica L. Guzman,
- Naveen Pemmaraju,
- Julianne Smith,
- Andrei Thomas-Tikhonenko,
- Marina Konopleva
Affiliations
- Tianyu Cai
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Agnès Gouble
- Cellectis SA
- Kathryn L. Black
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
- Anna Skwarska
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Ammar S. Naqvi
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
- Deanne Taylor
- Department of Biomedical & Health Informatics, Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
- Ming Zhao
- School of Health Professions, The University of Texas MD Anderson Cancer Center
- Qi Yuan
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- Mayumi Sugita
- Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine
- Qi Zhang
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Roman Galetto
- Cellectis SA
- Stéphanie Filipe
- Cellectis SA
- Antonio Cavazos
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Lina Han
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Vinitha Kuruvilla
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Helen Ma
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Connie Weng
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Chang-Gong Liu
- Department of Experimental Therapeutics, The University of MD Anderson Cancer Center
- Xiuping Liu
- Department of Experimental Therapeutics, The University of MD Anderson Cancer Center
- Sergej Konoplev
- Department of Hematopathology, The University of MD Anderson Cancer Center
- Jun Gu
- School of Health Professions, The University of Texas MD Anderson Cancer Center
- Guilin Tang
- Department of Hematopathology, The University of MD Anderson Cancer Center
- Xiaoping Su
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
- Gheath Al-Atrash
- Department of Stem Cell Transplantation and Cellular Therapy, The University of MD Anderson Cancer Center
- Stefan Ciurea
- Department of Stem Cell Transplantation and Cellular Therapy, The University of MD Anderson Cancer Center
- Sattva S. Neelapu
- Department of Lymphoma and Myeloma, The University of MD Anderson Cancer Center
- Andrew A. Lane
- Dana-Farber Cancer Institute
- Hagop Kantarjian
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Monica L. Guzman
- Department of Medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine
- Naveen Pemmaraju
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- Julianne Smith
- Cellectis SA
- Andrei Thomas-Tikhonenko
- Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
- Marina Konopleva
- Department of Leukemia, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-022-29669-8
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy derived from the precursors of plasmacytoid dendritic cells. Here the authors characterize the anti-tumor activity of allogeneic anti-CD123 CAR-T cells in preclinical models of BPDCN.
